Patients with myeloma with outpatient prescription drug coverage were more likely to receive oral targeted agents instead of parenteral chemotherapy, thereby increasing their chances of survival, according to a study of Medicare Part D enrollees published in Journal of Clinical Oncology. Adjustments to coverage policies allowed for patient access to optimal treatments, according to the researchers....Continue Reading

Clarithromycin plus bortezomib does not confer any additional efficacy and is a toxic combination among patients with multiple myeloma (MM), according to a study published in Experimental Hematology & Oncology. Evidence from previous studies suggested that clarithromycin may lead to synergistic effects in treatment regimens with immunomodulatory drugs for MM, such as lenalidomide plus dexamethasone, but there...Continue Reading